Skip to content
10-Q

Quarterly Report

Neuphoria Therapeutics Inc. NEUP

0000950170-25-075175

← back to feed
Filed
May 20, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · May 16, 2025 1.88M sh
Current Liabilities Q3 2025 · Mar 31, 2025 $1.55M
Current Liabilities Q3 2025 · Jun 30, 2024 $3.83M
Total Liabilities Q3 2025 · Mar 31, 2025 $4.72M
Total Liabilities Q3 2025 · Jun 30, 2024 $10.16M
Current Assets Q3 2025 · Mar 31, 2025 $17.09M
Current Assets Q3 2025 · Jun 30, 2024 $13.19M
Total Assets Q3 2025 · Mar 31, 2025 $30.71M
Total Assets Q3 2025 · Jun 30, 2024 $27.65M
Rd Expense Q3 2025 · Mar 31, 2025 $1.62M
Rd Expense Q3 2025 · Mar 31, 2025 $5.25M
Rd Expense Q3 2025 · Dec 31, 2024 $1.87M
Rd Expense Q3 2025 · Dec 31, 2024 $3.77M
Rd Expense Q3 2025 · Mar 31, 2024 $1.2M
Rd Expense Q3 2025 · Mar 31, 2024 $6.32M
Sga Expense Q3 2025 · Dec 31, 2024 $2.83M
Sga Expense Q3 2025 · Dec 31, 2024 $4.5M
Sga Expense Q3 2025 · Mar 31, 2024 $1.2M
Sga Expense Q3 2025 · Mar 31, 2024 $6.09M
Cash And Equivalents Q3 2025 · Jun 30, 2024 $12.61M
Cash And Equivalents Q3 2025 · Mar 31, 2024 $8.43M
Net Income Q3 2025 · Jun 30, 2024 −$15.5M
Net Income Q3 2025 · Mar 31, 2024 −$2.78M
Net Income Q3 2025 · Mar 31, 2024 −$12.81M
Net Income Q3 2025 · Dec 31, 2023 −$4.55M
Net Income Q3 2025 · Sep 30, 2023 −$5.47M
Shares Diluted Q3 2025 · Mar 31, 2024 981.04K sh
Shares Diluted Q3 2025 · Mar 31, 2024 842.43K sh
Operating Cash Flow Q3 2025 · Mar 31, 2024 −$11.67M
Stockholders Equity Q3 2025 · Mar 31, 2024 $17.95M
Stockholders Equity Q3 2025 · Dec 31, 2023 $19.5M
Stockholders Equity Q3 2025 · Sep 30, 2023 $17.23M
Stockholders Equity Q3 2025 · Jun 30, 2023 $22.01M
Eps Diluted Q3 2025 · Mar 31, 2024 −$2.83
Eps Diluted Q3 2025 · Mar 31, 2024 −$15.20
Eps Basic Q3 2025 · Mar 31, 2024 −$2.83
Eps Basic Q3 2025 · Mar 31, 2024 −$15.20
Operating Income Q3 2025 · Mar 31, 2024 −$2.39M
Operating Income Q3 2025 · Mar 31, 2024 −$12.41M